$NEO 2 year climber $8.99
Nasdaq CM
called 10/3/13 $3.02
Website
Shares Outstanding: 77.12M
Float: 46.56M
% Held by Insiders: 17.47%
% Held by Institutions: 60.90%
Shares Short (as of Apr 29, 2016): 2.89M
Short Ratio (as of Apr 29, 2016): 8.89
Short % of Float (as of Apr 29, 2016): 5.31%
Shares Short (prior month): 2.71M
Headlines
NeoGenomics, Inc., through its subsidiaries, operates a network of cancer-focused genetic testing laboratories providing genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, and other laboratories in the United States. It offers cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; immunohistochemistry and digital imaging testing services to localize proteins in cells of a tissue section, as well as to allow clients to see and utilize scanned slides, and perform quantitative analysis for certain stains; and molecular testing services that focus on the analysis of DNA and RNA, and the structure and function of genes at the molecular level. The company also provides pathology consultation services for clients in which its pathologists review surgical samples on a consultative basis; and testing services in support of its pharmaceutical clients oncology programs, as well as acts as a reference laboratory supplying anatomic pathology testing services. NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida.
Nasdaq CM
called 10/3/13 $3.02
Website
Shares Outstanding: 77.12M
Float: 46.56M
% Held by Insiders: 17.47%
% Held by Institutions: 60.90%
Shares Short (as of Apr 29, 2016): 2.89M
Short Ratio (as of Apr 29, 2016): 8.89
Short % of Float (as of Apr 29, 2016): 5.31%
Shares Short (prior month): 2.71M
Headlines
NeoGenomics, Inc., through its subsidiaries, operates a network of cancer-focused genetic testing laboratories providing genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, and other laboratories in the United States. It offers cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; immunohistochemistry and digital imaging testing services to localize proteins in cells of a tissue section, as well as to allow clients to see and utilize scanned slides, and perform quantitative analysis for certain stains; and molecular testing services that focus on the analysis of DNA and RNA, and the structure and function of genes at the molecular level. The company also provides pathology consultation services for clients in which its pathologists review surgical samples on a consultative basis; and testing services in support of its pharmaceutical clients oncology programs, as well as acts as a reference laboratory supplying anatomic pathology testing services. NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida.
